Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease(360 views) Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
Keywords: [111in-Dtpa0], Mibg Scintigraphy, Neuroendocrine Tumors, Octreotide Scintigraphy, Pheochromocytoma, Von Hippel-Lindau Disease, (3 Iodobenzyl)guanidine I 131, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Octreotide[3 Tyrosine] Y 90, C Peptide, Catecholamine, Gastrin, Insulin, Iopromide, Lysine, Neuron Specific Enolase, Pentetreotide In 111, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, 111in Octreotide, Dtpa(0), 111in-Octreotide, Diagnostic Agent, Drug Derivative, Indium, Pentetic Acid, Adrenalectomy, Adult, Angioma, Article, Blood Toxicity, Case Report, Contrast Enhancement, Diagnostic Value, Female, Follow Up, Genetic Association, Genetic Counseling, Human, Human Tissue, Hypertension, Immunohistochemistry, In Vitro Study, In Vivo Study, Liver Metastasis, Multiple Cycle Treatment, Pancreas Tumor, Pancreaticoduodenectomy, Paraganglioma, Pedigree Analysis, Protein Expression, Retina Tumor, Scintiscanning, Spiral Computer Assisted Tomography, Tachycardia, Treatment Refusal, Tumor Volume, Von Hippel Lindau Disease, Whole Body Scintiscanning, Computer Assisted Emission Tomography, Methodology, Indium Radioisotopes, Emission-Computed, (3 Iodobenzyl) Guanidine I 131, 10 Tetraacetic Acid Octreotide [3 Tyrosine] Y 90, Dtpa (0),
Affiliations: *** IBB - CNR ***
Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
Department of Endocrinological and Metabolic Sciences (DISEM), University of Genoa, Genoa, Italy
Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy
References: Maher, E.R., Iselius, L., Yates, J.R., Von Hippel-Lindau disease: A genetic study (1991) J Med Genet, 28, pp. 443-44
Latif, F., Tory, K., Gnarra, J., Identification of the von Hippel-Lindau disease tumor suppressor gene (1993) Science, 260, pp. 1317-1320
Ong, K.R., Woodward, E.R., Killick, P., Lim, C., Macdonald, F., Maher, E.R., Genotype-phenotype correlations in von Hippel-Lindau disease (2007) Hum Mutat, 28, pp. 143-149
Weirich, G., Klein, B., Wohl, T., Engelhardt, D., Brauch, H., VHL2C phenotype in a german von Hippel-Lindau family with concurrent VHL gemline mutations P81S and L188V (2002) J Clin Endocrinol Metab, 87, pp. 5241-5246
Choyke, P.L., Glenn, G.M., Walther, M.M., Patronas, N.J., Linehan, W.M., Zbar, B., von Hippel-Lindau disease: Genetic, clinical and imaging features (1995) Radiology, 194, pp. 629-642
Choyke, P.L., Filling-Katz, M.R., Shawker, T.H., von Hippel-Lindau disease: Radiologic screening for visceral manifestations (1990) Radiology, 174, pp. 815-820
Janson, E.T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother Biol Response Modif, 21, pp. 535-546
Duet, M., Sauvaget, E., Pételle, B., Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck (2003) J Nucl Med, 44, pp. 1767-1774
Kaltsas, G., Rockall, A., Papadogias, D., Reznek, R., Grossman, A.B., Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours (2004) Eur J Endocrinol, 151, pp. 15-27
Duet, M., Guichard, J.P., Rizzo, N., Boudiaf, M., Herman, P., Tran, Ba Huy, P., Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? (2005) Laryngoscope, 115, pp. 1381-1384
Shojamanesh, H., Gibril, F., Louie, A., Prospective study of the antitumor efficacy of longterm octreotide treatment in patients with progressive metastatic gastrinoma (2002) Cancer, 94, pp. 331-343
Bodei, L., Cremonesi, M., Grana, C., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours (2004) Eur J Nucl Med Mol Imaging, 31, pp. 1038-1046
Waldherr, C., Pless, M., Maecke, H.R., Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC (2002) J Nucl Med, 43, pp. 610-616
Libutti, S.K., Choyke, P.L., Bartlett, D.L., Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: Diagnostic and management recommendations (1998) Surgery, 124, pp. 1153-1159
Ferone, D., van Hagen, M.P., Kwekkeboom, D.J., Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro (2000) J Clin Endocrinol Metab, 85, pp. 1719-1726
Heppeler, A., Froidevaux, S., Mäcke, H.R., Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy (1999) Chem Eur J, 5, pp. 1016-1023
Chinol, M., Bodei, L., Cremonesi, M., Paganelli, G., Receptor-mediated radiotherapy with 90YDOTA-D-Phe1-Tyr3-octreotide: The experience of the European Institute of Oncology group (2002) Semin Nucl Med, 32, pp. 141-147
Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Camera, L., Biondi, B., Daniele, S., Screening in von Hippel-Lindau disease: Concurrent pheochromocytomas, paragangliomas and spinal hemangioblastomas revealed by helical-CT, MIBG scintigraphy and MRI in an asymptomatic patient (2003) European Journal of Radiology Extra, 48, pp. 8-13
Opocher, G., Conton, P., Schiavi, F., Macino, B., Mantero, F., Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1 (2005) Fam Cancer, 4, pp. 13-16
Lenders, J.W., Eisenhofer, G., Mannelli, M., Pacak, K., Phaeochromocytoma (2005) Lancet, 366, pp. 665-675
Neumann, H.P., Bausch, B., McWhinney, S.R., Germ-line mutations in nonsyndromic pheochromocytoma (2002) N Engl J Med, 346, pp. 1459-1466
Hoefnagel, C.A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours (1994) Eur J Nucl Med, 25, pp. 561-581
Tenenbaum, F., Lumbroso, J., Schlumberger, M., Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma (1995) J Nucl Med, 36, pp. 1-6
van der Harst, E., de Herder, W., Bruining, H.A., 1231-Metaiodobenzylguanidine and 111In-Octreotide uptake in benign and malignant pheochromocytomas (2001) J Clin Endocrinol Metab, 86, pp. 685-693
Kwekkeboom, D.J., van Urk, H., Pauw, B.K., Octreotide scintigraphy for the detection of paragangliomas (1993) J Nucl Med, 34, pp. 873-878
Schmidt, M., Fischer, E., Dietlein, M., Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1571-1580
Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24, pp. 28-47
Mukhopadhyay, B., Sahdev, A., Monson, J.P., Besser, G.M., Reznek, R.H., Chew, S.L., Pancreatic lesions in von Hippel-Lindau disease (2002) Clin Endocrinol (Oxf), 57, pp. 603-608
Lamberts, S.W., Hofland, L.J., van Koetsveld, P.M., Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localisation and therapy (1990) J Clin Endocrinol Metab, 71, pp. 566-574
Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients (1993) Eur J Nucl Med, 20, pp. 716-731
Chiti, A., Fanti, S., Savelli, G., Romeo, A., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours (1998) Eur J Nucl Med, 25, pp. 1396-1403
Reubi, J.C., Waser, B., Laissue, J.A., Gebbers, J.O., Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: In vitro identification (1992) Cancer Res, 56, pp. 1922-1931
Reubi, J.C., Kvols, L., Somatostatin receptors in human renal cell carcinomas (1992) Cancer Res, 52, pp. 6074-6078
Eriksson, B., Oberg, K., Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook (1999) Ann Oncol, 10 (SUPPL. 2), pp. S31-S38
Kvols, L.K., Moertel, C.G., O'Connell, M.J., Schutt, A.J., Rubin, J., Hahn, R.G., Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315, pp. 663-666
Maher, E. R., Iselius, L., Yates, J. R., Von Hippel-Lindau disease: A genetic study (1991) J Med Genet, 28, pp. 443-44
Ong, K. R., Woodward, E. R., Killick, P., Lim, C., Macdonald, F., Maher, E. R., Genotype-phenotype correlations in von Hippel-Lindau disease (2007) Hum Mutat, 28, pp. 143-149
Choyke, P. L., Glenn, G. M., Walther, M. M., Patronas, N. J., Linehan, W. M., Zbar, B., von Hippel-Lindau disease: Genetic, clinical and imaging features (1995) Radiology, 194, pp. 629-642
Choyke, P. L., Filling-Katz, M. R., Shawker, T. H., von Hippel-Lindau disease: Radiologic screening for visceral manifestations (1990) Radiology, 174, pp. 815-820
Janson, E. T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother Biol Response Modif, 21, pp. 535-546
Libutti, S. K., Choyke, P. L., Bartlett, D. L., Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: Diagnostic and management recommendations (1998) Surgery, 124, pp. 1153-1159
Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Lenders, J. W., Eisenhofer, G., Mannelli, M., Pacak, K., Phaeochromocytoma (2005) Lancet, 366, pp. 665-675
Neumann, H. P., Bausch, B., McWhinney, S. R., Germ-line mutations in nonsyndromic pheochromocytoma (2002) N Engl J Med, 346, pp. 1459-1466
Hoefnagel, C. A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours (1994) Eur J Nucl Med, 25, pp. 561-581
Kwekkeboom, D. J., van Urk, H., Pauw, B. K., Octreotide scintigraphy for the detection of paragangliomas (1993) J Nucl Med, 34, pp. 873-878
Hofland, L. J., Lamberts, S. W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24, pp. 28-47
Lamberts, S. W., Hofland, L. J., van Koetsveld, P. M., Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localisation and therapy (1990) J Clin Endocrinol Metab, 71, pp. 566-574
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] - and [123I-Tyr3] -octreotide: The Rotterdam experience with more than 1000 patients (1993) Eur J Nucl Med, 20, pp. 716-731
Reubi, J. C., Waser, B., Laissue, J. A., Gebbers, J. O., Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: In vitro identification (1992) Cancer Res, 56, pp. 1922-1931
Reubi, J. C., Kvols, L., Somatostatin receptors in human renal cell carcinomas (1992) Cancer Res, 52, pp. 6074-6078
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., Hahn, R. G., Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315, pp. 663-666
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease
The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrast-enhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and 131I-metaiodobenzylguanidine-scintigraphy. The role of 111-indium-diethylenetriaminepentaacetic acid [111In-DTPA0] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [111In-DTPA0] octreoticle scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by 90Y-1, 4, 7, 10-Tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA0) -Tyr3-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [111In-DTPA0] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes. 2008, Editrice Kurtis
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease